SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd (INDO) is witnessing an intense community debate following an unexpected sharp sell-off, despite surging crude oil prices and geopolitical tensions propelling other energy stocks higher. Many investors are questioning if the downturn is due to corporate dilution or market manipulation, drawing parallels to its history of extreme volatility.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as global LNG prices surge following Qatar's production halt and disrupted shipping through the Strait of Hormuz. The community is actively debating the company's strong Q4 earnings, recent legal win against Shell, and new supply agreements as catalysts positioning it to benefit from the volatile energy market, despite some analyst concerns about future oversupply.

Kraken Robotics, Inc. engages in the design, manufacture, and sale of software-centric sensors, subsea batteries, thrusters and underwater robotic systems. It operates through the following geographical segments: Asia Pacific, Europe, Middle East and Africa, North America, and Other. The company was founded on May 14, 2008, and is headquartered in Mt. Pearl, Canada.

Kraken Robotics Inc

Kraken Robotics is trending intensely following a trading halt for pending news, sparking widespread community speculation around a potential acquisition or major contract. Investors are highly bullish on its advanced underwater drone and battery technology, bolstered by significant partnerships in the rapidly expanding global defense sector.

Target Corp. engages in the operation and ownership of general merchandise stores. It offers food and general merchandise, clothing and household goods, electronics, and toys. Its brands include A New Day, All in Motion, Art Class, Auden, AVA & VIV, Boots and Barkley, Brightroom, Bullseye's Playground, Casaluna, Cat & Jack, Cloud Island, Colsie, dealworthy, Embark, Everspring, Favorite Day, Figmint, Future Collective, Gigglescape, Good & Gather, Goodfellow & Co, Hearth & Hand with Magnolia, Heyday, Hyde & EEK! Boutique, JoyLab, Kindfull, Kona Sol, Made By Design, Market Pantry, Mondo Llama, More Than Magic, Opalhouse, Open Story, Original Use, Pillowfort, Project 62, Room Essentials, Shade & Shore, Smartly, Smith & Hawken, Sonia Kashuk, Spritz, Sun Squad, Threshold, Universal Thread, up&up, Wild Fable, Wondershop, Xhilaration, California Roots, Casa Cantina, The Collection, Headliner, Jingle & Mingle, Rosé Bae, Photograph, SunPop, and Wine Cube. The company was founded by George Draper Dayton in 1902 and is headquartered in Minneapolis, MN.

Target Corp

Target is trending after delivering stronger-than-expected earnings and projecting a return to sales growth, sparking widespread bullish sentiment about its strategic turnaround under new leadership. The community is actively discussing potential price target raises and the stock's significant rebound, viewing it as undervalued compared to retail peers.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending with strong community conviction fueled by the anticipated imminent, positive Phase 3 trial results for its AML cancer treatment, GPS, which many believe will lead to a significant buyout. This optimistic outlook, coupled with considerable short interest, is driving aggressive buying and short squeeze speculation, with the stock showing notable strength despite broader market weakness.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike is trending amid a significant sell-off across the cybersecurity sector, fueled by fears that AI tools like Anthropic's Claude could disrupt traditional software models, though many in the community believe these concerns are overblown and that AI will ultimately increase the demand for advanced cyber defense.

SSgA Active Trust - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

XLE is trending as escalating Middle East conflicts, particularly around the Strait of Hormuz and reports of tanker attacks, drive an oil panic premium and raise concerns about global supply disruptions. The community is debating whether this surge in energy equities will be sustained or if the "war premium" is a shorting opportunity.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Senseonics is trending following strong Q4 revenue growth, a new in-house commercialization strategy, the integration of its Eversense 365 CGM with Sequel's twiist AID system, and European CE Mark approval; however, the community is sharply divided between belief in its superior technology and deep frustration with management's execution.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in November 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB is driving significant community discussion and volatility after a post-earnings sell-off, despite beating Q4 expectations, due to softer forward guidance and recent leadership changes. Investors are sharply divided between those buying the dip on strong fundamentals and AI relevance, and others anticipating further declines amid broader software sector concerns.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is trending after its mixed Q4 earnings and conservative 2026 guidance led to a price dip, with many in the community viewing it as a significant buying opportunity. While VEVYE sales missed near-term expectations, investors are keenly discussing the drug's recent Tier 1 formulary win with CVS and the earlier-than-expected OPUVIZ launch as potent catalysts for substantial future revenue growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Apollomics shares fell 16% after-hours on Wednesday, even as the company said Nasdaq confirmed it remains in compliance with continued listing requirements, canceling a delisting appeal hearing.&nbsp;Trading in the company’s shares and warrants was halted on Sept. 17 for additional information.Reversal Of Wind-Up PlansThe update came as Apollomics continues to stabilize operations following financial challenges that nearly led to its shutdown. In August, the company announced plans to discontinue all clinical trial activities and wind up its business due to funding shortages.&nbsp;The company later reversed those plans in early September after receiving $4.1 million in PIPE investments and appointing a new management team led by CEO Hung-wen Chen, COO Yi-kuei Chen, and CFO Peter Lin.Focus On Late-Stage Oncology PipelineWith new funding and leadership, Apollomics said it is continuing its global Phase 2 SPARTA clinical trial for its lead drug candidate APL-101, a selective c-Met inhibitor for non-small cell lung cancer and other tumors with c-Met alterations.&nbsp;Apollomics said its lead cancer drug APL-101 has delivered encouraging results in more than 280 patients and remains at the center of its cancer research plans.The company added that its clinical trial partners have all been paid, and work is continuing without interruption. It has also implemented a 12-month plan to maintain its drug pipeline's momentum and ensure&nbsp;the company's financial stability during the next phase of development.Global Expansion PlansApollomics said it plans to leverage its existing China approvals for APL-101 in MET-amplified lung cancer and glioblastoma as a springboard for regulatory filings in Southeast Asia, the Middle East and other emerging markets.The company said it now has 12 employees and expects to have 15 employees by the end of October 2025. The company also expects to shift more roles from China to the U.S. and Taiwan to strengthen operations and ensure that its late-stage cancer drug programs remain on track.Stocktwits Traders Stay Upbeat Despite VolatilityOn Stocktwits, retail sentiment for Apollomics was ‘extremely bullish’ amid a 329% message volume.One user noted that the stock was in a very good position after being halted during the recent market pivot, while another highlighted the ongoing volatility in Apollomics shares.<stembedurl>https://stocktwits.com/Love_To_Learn/message/632496720</stembedurl><stembedurl>https://stocktwits.com/topstockalerts/message/632436028</stembedurl><a href="https://stocktwits.com/symbol/APLM">Apollomics’ stock</a> has doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Apollomics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Apollomics Stock Nosedived 16% After-Hours Today

The stock fell after-hours even after Nasdaq confirmed the biotech had regained compliance with listing standards.

Equity

Apollomics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of oncology therapies to address unmet medical needs. The company was founded by Liang Yu Guo and Sanjeev Redkar in May 2015 and is headquartered in Foster City, CA.

Current Price	$19.85
Prev Close	$20.17
Open	$19.85
Dividend Yield	0.00%
50-Day Moving Average	$19.52
Beta	0.40
Avg. Volume	12,483.36
PE Ratio	-0.71

52-Week High	$42.12
52-Week Low	$3.66
Market Capitalization	$22.25M
EPS (Annual)	-$52.80
Price to Book	4.57
Revenue Per Employee	$0.00

APLM
Apollomics Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Fundamentals

Info

Latest APLM News

APLMApollomics Inc - Ordinary Shares - Class A